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Vaccines are needed to combat the global rise in fungal diseases. In this issue of Cell Host & Microbe,
Wu¨thrich et al. (2015) identify calnexin as a target of antigen-specific CD4 T cell responses against multiple
fungal pathogens. This study illustrates that a conserved epitope triggers convergent cell-mediated immune
responses to confer heterologous antifungal immunity.Vaccines represent one of the most sig-
nificant accomplishments in medicine
and public health. Smallpox, the virus
targeted by Edward Jenner over two
centuries ago, was eradicated worldwide
in 1979, and ongoing vaccination cam-
paigns have led to the near-eradication
of polio and the prevention of innumerable
deaths by other viral pathogens, including
influenza, hepatitis A and B, measles,
mumps, and rubella. Vaccines directed
against cholera, plague, typhoid fever,
diphtheria, pertussis, and tetanus have
been similarly effective in decreasing the
global burden of these bacterial diseases.
In contrast, there are no licensed vaccines
against human fungal pathogens despite
the increasing global disease burden
fueled by the AIDS pandemic, advances
in medical technologies (i.e., transplan-
tation, immunosuppression), the emer-
gence of novel fungal pathogens (e.g.,
Cryptococcus gattii), and the geographic
expansion of primary fungal pathogens
(e.g., Coccidioides posadasii and immitis)
due to climate change (Brown et al., 2012;
Cassone and Casadevall, 2012). Collec-
tively, invasive fungal infections (IFIs) are
estimated to cause 1–2 million human
deaths across the globe annually, high-
lighting the need for vaccine development
against this increasingly important class
of pathogens (Brown et al., 2012). In a
step toward achieving this goal, in
this issue of Cell Host and Microbe,
Wu¨thrich and colleagues identify a widely
conserved CD4 T cell fungal epitope that
binds a peptide derived from fungal cal-
nexin (Wu¨thrich et al., 2015). Calnexin, pri-
marily known for its chaperone function
in the ER of mammalian cells, is displayed
on the cell surface of diverse fungi, andits inclusion in vaccine formulations in-
duces resistance against multiple fungal
pathogens in murine models of vaccine
immunity.
These findings mark an advance, as
vaccine development for fungal diseases
has far lagged behind other infectious
diseases, hampered by conceptual chal-
lenges such as the genetic complexity
and experimental intractability of many
fungal organisms, limited knowledge
regarding mechanisms of antifungal
immunity, as well as minimal financial
investment (Cassone and Casadevall,
2012). The medical need for antifungal
vaccines coupled with significant ad-
vances in our understanding of antifungal
immunity over the past 1–2 decades
has prompted a renewed interest in this
field (Cassone and Casadevall, 2012),
particularly since many examples of
mucosal (e.g., vulvovaginal candidiasis)
and invasive fungal diseases (e.g., blasto-
mycosis, coccidioidomycosis, histoplas-
mosis) are not limited to hosts with
impaired cell-mediated or humoral immu-
nity. Multiple preclinical studies in animal
models demonstrate the feasibility of
diverse vaccination strategies to induce
immunity against clinically relevant fungi
including Candida, Aspergillus, Crypto-
coccus, Blastomyces, Histoplasma, and
Coccidioides species (Nanjappa and
Klein, 2014). The successful completion
of Phase I trials for two antifungal vac-
cines that target Candida albicans show
promise that antifungal vaccines will be
approved for use in humans (Cassone
and Casadevall, 2012; Schmidt et al.,
2012).
Traditional vaccine preparations exploit
the fine specificity of adaptive immunityCell Host & Microbto target one or more antigens found
in a single microorganism to confer
homologous protection. However, proof-
of-principle studies support the concept
of generating ‘‘universal’’ vaccines that
target multiple heterologous pathogens
via conserved target antigens. While we
favor the term ‘‘broadly reactive,’’ such
vaccines can, in principle, targetmicrobial
pathogens across different kingdoms
to confer cross-kingdom protection (see
below). In the case of calnexin-dependent
fungal vaccination strategies, the work
of Wu¨thrich and colleagues supports the
further development of a broadly reactive
antifungal vaccine that would have clear
financial and medical benefits over the
generation and testing of multiple fungal
species-specific vaccine candidates.
In prior studies, Wu¨thrich and Klein
generated T cell receptor transgenic
mice (TCR-Tg), also called 1807 mice,
using a clone of CD4 T cells isolated
from mice infected with Blastomyces
dermatitidis, the causative agent of
blastomycosis (Wu¨thrich et al., 2011b).
The investigators found, surprisingly,
that 1807 TCR-Tg cells expanded not
only after infection with Blastomyces
dermatitidis, but also after challenge with
other dimorphic fungi including Histo-
plasma capsulatum and Coccidioides
posadasii (Wu¨thrich et al., 2011a).
Moreover, adoptive transfer of 1807
TCR-Tg cells conferred protection
against challenge with these dimorphic
fungal pathogens, suggesting that the
epitope recognized by the 1807 TCR-Tg
cells is a common immunogenic antigen
expressed by these fungi (Wu¨thrich
et al., 2011a, 2011b). In the current
study, Wu¨thrich and colleagues identify ae 17, April 8, 2015 ª2015 Elsevier Inc. 421
Figure 1. Vaccination with Calnexin Activates ‘‘Pan-Fungal’’ CD4 T Cells
The ER-associated protein calnexin is expressed on the surface of fungal cells. A conserved calnexin pep-
tide is recognized by 1807 TCR-Tg cells and endogenous fungus-specific CD4 T cells. Calnexin-specific
CD4 T cells are broadly reactive against multiple pathogenic ascomycetes. Vaccination with calnexin
formulated with Adjuplex or glucan particles leads to the activation and differentiation of CD4 T cells pro-
tective against dimorphic fungi.
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fungal calnexin as the antigenic epitope
recognized by 1807 TCR-Tg cells
(Figure 1). Remarkably, bioinformatics an-
alyses reveal that the calnexin epitope is
expressed not only in dimorphic fungi, as
predicted from their previous studies, but
also in a number of clinically relevant
members of the phylum ascomycetes
(sac fungi), including Aspergillus species
and Fonsecaea pedrosoi, an agent of
chromoblastomycosis, a chronic disfigur-
ing fungal disease of the skin and soft
tissues.
The authors generated calnexin pep-
tide-MHC II tetramers to measure the
expansion of endogenous, fungus-spe-
cific CD4 T cells following challenge with
Blastomyces dermatitidis, Histoplasma
capsulatum, Fonsecaea pedrosoi, and
Aspergillus fumigatus and demonstrated
a conserved antifungal immune response
toward this epitope. The question of
whether calnexin-reactive CD4 T cell
expansion represents an immunodomi-
nant response toward homologous and
heterologous fungal pathogens remains
undefined and an important future area422 Cell Host & Microbe 17, April 8, 2015 ª2of investigation. Nevertheless, vaccine
formulations that contain fungal calnexin
embedded in glucan particles or the
adjuvant Adjuplex could induce fungus-
specific CD4 T cell expansion, reduce
the fungal burden, and prolong survival
upon challenge with Blastomyces derma-
titidis orCoccidioides posadasii (Figure 1).
Moreover, in a pilot study, the authors
assayed and found calnexin-specific
CD4 T cells in humans with a history of
prior infection or exposure to Blastomy-
ces dermatitidis. In aggregate, this new
study demonstrates the possibility of
exploiting a conserved calnexin antigen
as a target for the development of
broadly reactive antifungal vaccines.
Beyond protecting against other fungal
organisms, broadly reactive vaccines
might be able to also protect across
microbial kingdoms. The anti-Candida
vaccine formulations currently in clinical
investigation target recurrent vulvovagi-
nal candidiasis and are univalent subunit
vaccines directed against the fungal
adhesin Als3p (agglutinin-like sequence
3 protein) or the extracellular protease
Sap2 (secreted aspartic protease 2)015 Elsevier Inc.(Cassone and Casadevall, 2012; Schmidt
et al., 2012). Interestingly, vaccination of
mice with recombinant Als3p resulted
in protection not only against intrave-
nous Candida albicans challenge but
also against bloodstream challenge
with Staphylococcus aureus bacteria
(Lin et al., 2009; Spellberg et al., 2008).
How can vaccination with a fungal
protein protect against infection with
bacteria? Immunization with Candida-
derived Als3p results in protection from
S. aureus challenge in a Th1- and Th17
CD4 T cell-dependent manner, indicating
a convergent vaccine mechanism (Lin
et al., 2009). Most likely, Staphylococcus
aureus encodes a structurally homolo-
gous epitope to the Candida albicans
Als3p vaccine epitope. In addition to
CD4 T cell-dependent vaccines, previous
studies have demonstrated that anti-
bodies against highly conserved fungal
moieties—for example, b-glucan poly-
saccharides found in the cell wall—can
confer protection against diverse fungal
organisms (Torosantucci et al., 2005).
Collectively, these studies in fungal vac-
cine development lay the groundwork
for non-traditional vaccine strategies that
confer protection against heterologous
pathogens via conserved epitopes,
either by structure or linear sequence,
that induce convergent mechanisms of
immunity. In this manner, antifungal
vaccines emphasize protective strategies
that are not based on the identity of the
pathogen, but on conserved molecular
structures that are exposed during fungal
growth in host tissues. This approach
is among the most promising attempts
to counter the growing threat and infec-
tious morbidity and mortality attributed
to fungal pathogens.ACKNOWLEDGMENTS
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Viruses possess elaborate defensive mechanisms to evade host innate immune responses. In this issue of
Cell Host & Microbe, Stavrou et al. (2015) reveal how the murine leukemia virus uses a sugar-protein shield
to protect from inevitable destruction by cellular innate immune factors including the APOBEC3 DNA
mutating enzyme.Mammalian cells have mechanisms to
protect from potentially harmful foreign
nucleic acids, including viral RNA and
DNA. Deficiencies in these mechanisms
can predispose to viral infections and
precipitate autoimmune diseases. For
instance, defects in a DNA exonuclease
(TREX1), a dNTP hydrolase (SAMHD1), a
double-stranded RNA editing enzyme
(ADAR1), an RNA/DNA hybrid endonu-
clease (RNaseH2), and a cytosolic RNA
receptor (MDA5) all lead to an infection-
like disease called Aicardi-Goutie`res syn-
drome (AGS) (Crow, 2013). The common
denominator is that these are all nucleic
acid-catabolizing proteins that participate
in pathways for sensing and/or clearing
away foreign and self-derived nucleic
acids. Presumably, defects in these pro-
teins lead to a build-up of stimulatory
nucleic acids that trick immune cells into
launching a continual antiviral response
characterized by high levels of interferon
(IFN) production and upregulation of
IFN-responsive genes, some of which
encode proteins listed above.In this issue, Stavrou and colleagues
(2015) use murine leukemia virus (MLV)
as an innate immune probe to deduce
how cells detect viral nucleic acids and
implement antiviral programs to limit
infection (Stavrou et al., 2015). MLV is a
distant retroviral relative of the AIDS
viruses HIV-1 and HIV-2. These and other
retroviruses use an enzyme called reverse
transcriptase (RT) to copy their RNA
genome into a double-stranded DNA
that inserts into the host cell genome.
Reverse transcription is an elegant
process that occurs within the relatively
safe confines of the viral capsid, a semi-
permeable lattice that shields the viral
nucleic acid from the harsh milieu of
the cell. Virus replication is thought to
advance almost to completion within the
capsid, and viral DNA is only exposed
to the cytosol for a short time, if at all,
before being inserted into the nuclear
genome. Interestingly, most natural
antiviral mechanisms target the reverse
transcription stage of the retrovirus life-
cycle, including SAMHD1, TRIM5a, andAPOBEC3 DNA cytosine deaminases
(Harris et al., 2012). It is therefore under-
standable that many antiretroviral drugs
also work by blocking this step of the viral
life cycle.
Prior work by the same group had
shown that the MLV capsid is more fragile
in viral variants lacking the amino-terminal
end of the capsid precursor polyprotein
Gag, which harbors several glycosylation
sites (Stavrou et al., 2013). Infection of a
murine macrophage cell line with glyco-
Gag mutant viruses results in elevated
IFN-b production, which skyrockets in
the absence of TREX1, presumably due
to the persistence of more immunostimu-
latory viral DNA replication intermediates.
The replication of glyco-Gag mutant vi-
ruses is strongly restricted by cellular
APOBEC3, as both glyco-Gag mutant
and non-mutant viruses are able to repli-
cate robustly and to similarly high levels
in APOBEC3 null animals. Moreover,
mutations that restore glyco-Gag function
frequently occurred in vivo, but only in
APOBEC3-expressing animals, implyinge 17, April 8, 2015 ª2015 Elsevier Inc. 423
